<DOC>
	<DOCNO>NCT02736656</DOCNO>
	<brief_summary>This multicenter , open-label extension study aim assess long-term safety efficacy SPN-812 ER administer alone conjunction Food Drug Administration-approved Attention Deficit Hyperactivity Disorder ( ADHD ) medication treatment ADHD pediatric subject participate previous blind study SPN-812 ER . All pediatric subject complete blind study SPN 812 ER option participate study subject receive SPN-812 ER . After initial dose , subject enter dose optimization phase three nine week . Following optimization , subject return clinic every 3 month subject discontinues study end 36 month .</brief_summary>
	<brief_title>Open-label Study Evaluate Long-term Safety Efficacy SPN-812 Extended Release ( ER )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<criteria>1 . Completion previous blind study SPN812 ER treatment ADHD . 2 . Continues medically healthy clinically normal laboratory profile , vital sign , electrocardiogram . 3 . Weight least 20 kg . 4 . Written Informed Consent obtain subject 's parent legally authorize representative ; write Informed Assent obtain subject appropriate . 1 . Diagnosis major depressive disorder , bipolar disorder , personality disorder , Tourette 's disorder , psychosis otherwise specify . 2 . Currently meet Diagnostic Statistical Manual Mental DisordersV criterion anxiety disorder primary diagnosis . 3 . Current evidence suicidality ( suicidal thought behavior ) . 4 . Body Mass Index great 95th percentile appropriate age gender . 5 . Pregnancy , refusal practice contraception study ( female subject childbearing potential ) . 6 . Current substance alcohol use . 7 . Any reason , opinion Investigator , would prevent subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>